Relay Therapeutics (RLAY) Equity Ratio (2020 - 2025)
Historic Equity Ratio for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to 0.91.
- Relay Therapeutics' Equity Ratio rose 56.98% to 0.91 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.91, marking a year-over-year increase of 56.98%. This contributed to the annual value of 0.89 for FY2024, which is 18.68% up from last year.
- According to the latest figures from Q3 2025, Relay Therapeutics' Equity Ratio is 0.91, which was up 56.98% from 0.91 recorded in Q2 2025.
- Over the past 5 years, Relay Therapeutics' Equity Ratio peaked at 0.95 during Q1 2021, and registered a low of 0.84 during Q2 2023.
- Moreover, its 5-year median value for Equity Ratio was 0.89 (2024), whereas its average is 0.88.
- Examining YoY changes over the last 5 years, Relay Therapeutics' Equity Ratio showed a top increase of 23369.11% in 2021 and a maximum decrease of 1042.08% in 2021.
- Quarter analysis of 5 years shows Relay Therapeutics' Equity Ratio stood at 0.89 in 2021, then dropped by 2.95% to 0.86 in 2022, then rose by 3.13% to 0.89 in 2023, then grew by 0.19% to 0.89 in 2024, then grew by 1.61% to 0.91 in 2025.
- Its Equity Ratio stands at 0.91 for Q3 2025, versus 0.91 for Q2 2025 and 0.9 for Q1 2025.